Seeking Alpha

Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of...

Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of its prostate cancer drug Xtandi by the FDA. Wedbush says that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for the drug is going to make it the market leader.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector